NEW YORK, Oct. 22 – NetGenics has licensed its DiscoveryCenter integration software product to Avalon Pharmaceuticals to help it integrate its genomic, cytogenetic, and chemistry data, Avalon said on Monday.

“We are building the next generation genomics drug discovery platform,'' Ken Carter PhD, Avalon's president and CEO, said in a statement. “DiscoveryCenter will play a key role in our success, as it provides us with the ability to integrate and analyze huge amounts of data, and NetGenics will provide a fundamental building block to our cutting edge bioinformatics platform.''

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.